Managing Complications of Androgen Deprivation Therapy for Prostate Cancer

Urologic Clinics of North America

Volumn 33, Issue 2, 2006, Pages 181-190

  Holzbeierlein, Jeffrey M ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANTIANDROGEN; ANTIDEPRESSANT AGENT; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLONIDINE; CYPROTERONE ACETATE; ESTROGEN; FLUTAMIDE; GABAPENTIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NILUTAMIDE; PAMIDRONIC ACID; PAROXETINE; RECOMBINANT ERYTHROPOIETIN; TRIPTORELIN; UNINDEXED DRUG; VENLAFAXINE; VITAMIN; ZOLEDRONIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUPUNCTURE; ANDROGEN DEPRIVATION THERAPY; ANEMIA; BEAM THERAPY; BLEEDING; BODY MASS; BONE NECROSIS; BREAST HYPERTROPHY; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR RISK; CARPAL TUNNEL SYNDROME; CASTRATION; CHILL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CONSTIPATION; DIET; DIGESTIVE SYSTEM ULCER; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG COST; DRUG FEVER; DRUG INDUCED DISEASE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DYSPNEA; EPIGASTRIC PAIN; ERECTILE DYSFUNCTION; ESOPHAGITIS; ESOPHAGUS ULCER; ESTROGEN THERAPY; EXERCISE; FATIGUE; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HEALTH CARE COST; HEMOGLOBINOPATHY; HORMONAL REGULATION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPHOSPHATEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; INCREASED APPETITE; INJECTION SITE REACTION; JAW DISEASE; KIDNEY DYSFUNCTION; LIBIDO DISORDER; LIPID METABOLISM; LOW DRUG DOSE; MASTALGIA; METABOLIC DISORDER; MONOTHERAPY; NAUSEA; NONHUMAN; ORCHIECTOMY; PAIN; PATIENT CARE; PATIENT COUNSELING; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REFLUX ESOPHAGITIS; REVIEW; SECONDARY OSTEOPOROSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SODIUM RETENTION; SOMNOLENCE; SOYBEAN; SYNCOPE; TREATMENT INDICATION; TREMOR; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; XEROSTOMIA;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HOT FLASHES; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 33646020391     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2005.12.008     Document Type: Review

References (66)

1. Huggins C., and Hodges C. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781-1788
3. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
4. Cooperberg M.R., Gorssfeld G.D., Lubeck D.P., et al. national practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 (2003) 981-989
5. Bonzani R.A., Stricker H.J., Peabody J.O., et al. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer. J Urol 160 (1998) 2446-2449
6. Schow D.A., Renfer L.G., Rozenski T.A., et al. Prevalence of hot flashes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 91 (1998) 855-857
7. Charig C.R. Flushing: long term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 33 (1989) 175-178
8. Karling P., Hammar M., and Varenhorst E. Prevalence and duration of hot flashes after surgical or medical castration in men with prostatic carcinoma. J Urol 152 (1994) 1170-1173
9. Smith J.A. Management of hot flushes due to endocrine therapy for prostate carcinoma. Oncology 10 (1996) 1319-1322
10. Smith J.A. A prospective comparison of treatments for symptomatic hot flashes following endocrine treatment for carcinoma of the prostate. J Urol 152 (1994) 132-134
11. Frodin T., Aluval G., and Varenhorst E. Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flashes after orchidectomy in patients with prostatic cancer. Prostate 7 (1985) 203-208
12. Loprinzi C.L., Michalak J.L., Quella S.K., et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 331 (1994) 347-352
13. Sartor O., and Eastham J.A. Progressive prostate cancer associated with the use of megestrol acetate administered for control of hot flashes. South Med J 92 (1998) 415-416
14. Dawson N.A., Conaway M., Halabi S., et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer 88 (2000) 825-834
15. Gerber G.S., Zagaja G.P., Ray P.S., et al. Transdermal estrogen in the treatment of hot flashes in men with prostate cancer. Urol 55 (2000) 97-101
16. Miller J.I., and Ahmann F.R. Treatment of castration induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer. Urology 40 (1992) 499-502
17. Loprinzi C.L., Pisansky T.M., Fonseca R., et al. Pilot evaluation of venlaflaxine hydrochloride for the therapy of hot flashes in cancer survivor. J Clin Oncol 16 (1998) 2377-2381
18. Quella S.K., Loprinzi C.L., Sloan J., et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 162 (1999) 98-102
19. Langenstroer P., Karmer B., Cutting B., et al. Parenteral medroxyprogesterone for the management of lutenizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol 174 (2005) 642-645
20. Hammar M., Grisk J., Grimes O., et al. Accupuncture treatment of vasomotor symptom sin men with prostatic carcinoma: a pilot study. J Urol 161 (1999) 853-856
21. Albertazzi P., Parsini F., Bonaccorsi G., et al. The effect of dietary soy supplementation on hot flashes. Obstet Gynecol 91 (1998) 6-11
22. Kronenberg F., and Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 137 (2002) 805
23. Barton D.L., Loprinzi C.L., Quella S.K., et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16 (1998) 495-500
24. Fugate S.E., and Church C.O. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Ann Pharmacother 38 (2004) 1482-1499
25. Jarry H., Thelen P., Chirstoffel V., et al. Cimicifuga racemosa extract BNO 1055 inhibits proliferation of the human prostate cancer cell line LNCaP. Phytomedicine 12 (2005) 178-182
26. Parra R.O., and Gregory J.L. Treatment of post-orchiectomy hot flashes with trasndermal administration of clonidine. J Urol 142 (1990) 753-754
27. Stearns V. Management of hot flashes in breast cancer survivors and men with prostate cancer. Curr Oncol Rep 6 (2004) 285-290
28. Jeffery S.M., Pepe J.J., Pupovich L.M., et al. Gabapentin for hot flashes in prostate cancer. Ann Pharmacother 36 (2002) 433-436
29. Cervenakov I., Kopecny M., Jancar M., et al. "Hot flush", an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate. Int Urol Nephrol 32 (2000) 72-79
30. Morote J., Martinez E., Trilla E., et al. Influence of the type and length of continuous androgen suppression in the development of osteoporosis in patients with prostate cancer. [abstract]. J Urol 169 Suppl (2003) 931
31. Stepan J.J., Lachman M., Zvioina J., et al. Castrated men exhibit bone loss effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrin Metab 69 (1989) 523-527
32. Melton J.L., Alothman K.I., Khosla S., et al. Fracture risk following bilateral orchiectomy. J Urol 169 (2003) 1747-1750
33. Stoch S.A., Parker R.A., Chen L., et al. Bone loss in men with prostate cancer treated with gonadotropin releasing hormone agonists. J Clin Endocrinol Metab 86 (2001) 27-37
34. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 152-164
35. Agarwal M.M., Khandelwal N., Mandal A.K., et al. Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer 103 (2005) 2042-2052
36. Smith M.R., Fallon M.A., and Goode M.J. Cross sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 61 (2003) 127-131
37. Wiren K., and Orwoll E. Androgens and bone: basic aspects. In: Orwoll E. (Ed). Osteoporosis in men (1989), Academic Press, San Diego (CA) 211-274
38. Smith E.B., Boyd J., Frank G.R., et al. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N Engl J Med 331 (1994) 1056-1061
39. Smith M.R., McGovern F.J., Fallon M.A., et al. Low bone mineral density in hormone naive men with prostate carcinoma. Cancer 91 (2001) 2238-2245
40. Seeman E., Melton L.J., O'Fallon W.M., et al. Risk factors for spinal osteoporosis in men. Am J Med 75 (1983) 977-983
41. Bilezikian J.P. Osteoporosis in men. J Clin Edocrinol Metab 84 (1999) 3431-3434
42. Orwoll E., Ettinger M., Weiss S., et al. Aledronate for the treatment of osteoporosis in men. N Engl J Med 343 (2000) 604-610
43. Segal R.J., Reid R.D., Courneya K.S., et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21 (2003) 1653-1659
44. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948-955
45. Lipton A., Small E., Saad F., et al. The new bisphosphonate Zometa (zolendronic acid) decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 20 Suppl 2 (2002) 45-54
46. Smith M.R., Eastham J.A., Gleason D.M., et al. Randomized controlled trial of zolendronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 (2003) 2008-2012
47. Major P.P., Lipton A., Berenson J., et al. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 61 (2000) 6-14
48. Cheer S.M., and Noble S. Zoledronic acid. Drugs 61 (2001) 799-805
49. Body J.J. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 4 Suppl 1 (2001) 49-53
50. Vannucchi A.M., Ficarra G., Antonioli E., et al. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 128 (2005) 738
51. Tayek J.A., Herber D., Byerly L.O., et al. Nutritional and metabolic effects of gonadotropin releasing hormone agonist treatment for prostate cancer. Metabolism 39 (1990) 1314-1319
52. Higano C.S., Ellis W., Russell K., et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48 (1996) 800-804
53. Smith M.R., Finklestein J.S., McGovern F.J., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocinol Metab 87 (2002) 599-602
54. Shannon J., Tewoderos S., Garzotto M., et al. Statins and prostate cancer risk: a case controlled study. Am J Epidemiol 162 (2005) 318-325
55. Strum S.B., McDermed J.E., Scholz M.C., et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79 (1997) 933-941
56. Baba K., Yajima M., Carrier S., et al. effect of testosterone on the number of NADPH diaphorase stained fibers in the rat corpus cavernosum and dorsal nerve. Urology 56 (2000) 533-538
57. Green H.J., Pakenham K.I., Headley B.C., et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone releasing hormone analogues and cyproterone acetate: a randomized controlled trial. Br J Urol 90 (2002) 427-432
58. Salminen E.K., Portin R.I., Koskinen A., et al. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 10 (2004) 7575-7582
59. Tan R.S. Andropause and testosterone supplementation for cognitive loss. J Androl 23 (2002) 45-46
60. Salminen E.K., Portin R.I., Koskinen A.I., et al. Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 103 (2005) 1381-1387
61. Akakura K., Bruchosvsky N., Goldberg S.L., et al. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 71 (1993) 2782-2790
62. Sato N., Gleave M.E., Bruchosvsky N., et al. Intermittent androgen suppression delays progression to androgen independent regulation of prostate specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol 58 (1996) 139-146
63. Grossfeld G.D., Small E.J., Lubeck D.P., et al. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology 58 (2001) 56-64
64. Jiang P.Y., and Higano S. the dynamics of bone mineral density during intermittent androgen suppression in prostate cancer patients without bone metastases. Proc Am Soc Clin Oncol (2002) [abstract 789a]
65. Tyrrell C.J., Kaisary A.V., Iversen P., et al. A randomized comparison of 'Casodex'(bicalutamide) 150mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33 (1998) 447-456
66. Iversen P., Tyrrell C.J., Kaiary A.V., et al. Bicalutamide monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 164 (2000) 1979-1982